Saturday, July 23, 2016 5:04:15 PM
A de novo application adds months to the clearance timeline.
A lot of bad things could happen in those months, like SEC action, a couple more quarters of disappointing revenues, and/or a reverse split.
Furthermore: none of the UK back pain studies are double-blinded controlled studies. Yes, the FDA agreed to look at them, but the FDA doesn't put much weight in testimonials and surveys.
BIEL needs the Oxford data to get the de novo cleared, IMO. I think that's exactly what Andy was saying in his radio interview.
Again -- I'm not LOOKING for negative things about BIEL. I see them, though. BIG difference.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM